Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BDTX 
Black Diamond Therapeutics Inc (BDTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: BDTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -43.84% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.23M USD | Price to earnings Ratio - | 1Y Target Price 13.4 |
Price to earnings Ratio - | 1Y Target Price 13.4 | ||
Volume (30-day avg) 5598328 | Beta 2.52 | 52 Weeks Range 1.54 - 7.66 | Updated Date 03/30/2025 |
52 Weeks Range 1.54 - 7.66 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate -0.3117 | Actual -0.28 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.71% | Return on Equity (TTM) -69.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14837177 | Price to Sales(TTM) - |
Enterprise Value 14837177 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.92 | Shares Outstanding 56662200 | Shares Floating 38983042 |
Shares Outstanding 56662200 | Shares Floating 38983042 | ||
Percent Insiders 2.72 | Percent Institutions 87.31 |
Analyst Ratings
Rating 4.57 | Target Price 14.5 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Black Diamond Therapeutics Inc
Company Overview
History and Background
Black Diamond Therapeutics Inc. was founded in 2014 and is a precision oncology medicine company discovering and developing MasterKey therapies to treat patients with genetically defined cancers. They focus on allosteric mutations.
Core Business Areas
- Oncology Drug Development: Focuses on developing small molecule, tumor-agnostic therapies targeting oncogenic mutations. Their lead programs target specific EGFR and HER2 alterations.
Leadership and Structure
The company is led by a management team with experience in drug discovery and development. The organizational structure includes research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- BDTX-1535: BDTX-1535 is an oral, selective inhibitor of EGFR with allosteric mutations. Currently in clinical trials for NSCLC and other solid tumors. Market share is currently 0 as the drug is not yet approved. Competitors include AstraZeneca's Tagrisso and other EGFR inhibitors, however, they don't cover the allosteric mutations BDTX-1535 is targeting.
- BDTX-4933: BDTX-4933 is an oral, selective inhibitor of HER2 with allosteric mutations. Currently in preclinical development. Market share is currently 0 as the drug is not yet approved. Competitors include Enhertu, but this therapy doesn't cover the allosteric mutations BDTX-4933 is targeting.
Market Dynamics
Industry Overview
The oncology drug market is large and growing, driven by increasing cancer incidence and advances in targeted therapies. Precision oncology is a key trend, with therapies tailored to specific genetic mutations.
Positioning
Black Diamond Therapeutics Inc. is positioned as a precision oncology company focused on developing MasterKey therapies for allosteric mutations. Their competitive advantage lies in their focus on this specific area of unmet need.
Total Addressable Market (TAM)
The TAM for precision oncology is estimated to be billions of dollars. Black Diamond Therapeutics Inc. is positioned to capture a portion of this market by targeting specific allosteric mutations with MasterKey therapies.
Upturn SWOT Analysis
Strengths
- Proprietary MasterKey drug discovery platform
- Focus on allosteric mutations
- Experienced management team
- Strong intellectual property position
- Promising preclinical and early clinical data
Weaknesses
- Clinical trial risk
- Dependence on key drug candidates
- Limited commercial infrastructure
- High cash burn rate
- Reliance on future financing
Opportunities
- Expansion of MasterKey platform to new targets
- Partnerships with larger pharmaceutical companies
- Potential for breakthrough therapy designation
- Expansion into new geographies
- Favorable regulatory environment for precision oncology therapies
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Changes in regulatory landscape
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
Competitive Landscape
Black Diamond Therapeutics Inc. faces competition from established pharmaceutical companies with larger resources and existing oncology portfolios. Their advantage lies in their focus on a specific niche within precision oncology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth trajectory based on clinical development and partnerships, not yet reflecting product sales.
Future Projections: Future projections are dependent on clinical trial success and regulatory approvals. Analyst estimates vary depending on the perceived probability of success of their drug candidates.
Recent Initiatives: Focus on advancing BDTX-1535 and BDTX-4933 through clinical trials.
Summary
Black Diamond Therapeutics is a precision oncology company with a focus on MasterKey therapies, targeting allosteric mutations. Their strength lies in their innovative platform and experienced team, but they face significant clinical trial and financial risks. Future success depends heavily on the success of their lead drug candidates and securing additional funding. Competition is high, but their targeted approach could provide a competitive edge if clinical trials prove successful.
Similar Companies
- AZN
- MRK
- BMY
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share is an estimate based on the market for potential therapies.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Black Diamond Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-01-30 | CEO, President & Chairman Dr. Mark A. Velleca M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | |
Full time employees 24 | |||
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.